Projects per year
Full Application for DoD Breakthrough Award Level 2: Targeting PTPN2 to promote anti-tumor immunity in triple negative breast cancer
1/03/21 → 29/02/24
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [MARIPOSA].
Richardson, G. & Lai, L. H.
26/02/21 → 31/12/23
Sparrow, M. P., Feb 2021, (Accepted/In press) In : Expert Opinion on Pharmacotherapy. 3 p.
Research output: Contribution to journal › Editorial › Other › peer-reviewOpen Access
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation: A Meta-analysisLim, Z. J., Subramaniam, A., Reddy, M. P., Blecher, G., Kadam, U., Afroz, A., Billah, B., Ashwin, S., Kubicki, M., Bilotta, F., Curtis, J. R. & Rubulotta, F., 1 Jan 2021, In : American Journal of Respiratory and Critical Care Medicine. 203, 1, p. 54-66 13 p.
Research output: Contribution to journal › Article › Research › peer-reviewOpen Access
Influence of timeliness and receipt of first treatment on geographic variation in non-small cell lung cancer mortalityWah, W., Stirling, R. G., Ahern, S. & Earnest, A., 15 Apr 2021, In : International Journal of Cancer. 148, 8, p. 1828-1838 11 p.
Research output: Contribution to journal › Article › Research › peer-review